Zynerba Pharma CS (ZYNE)
$8.26 0.19 (2.25%)
19:10 EDT ZYNE Stock Quote Delayed 15 Minutes
Previous Close $8.26
Market Cap 112.02M
PE Ratio -2.96
Volume (Avg. Vol.) 1.45M
Day's Range 7.92 - 8.43
52-Week Range 2.75 - 16.47
Dividend & Yield N/A (N/A)
ZYNE Stock Predictions, Articles, and Zynerba Pharma CS News
- From InvestorPlace
- From the Web
By David Moadel
Thinking about investing in medical cannabis? ZYNE stock is a lesser-known gem with transformative potential.
Looking for the real gains among the marijuana stocks? The key is to focus on firms using cannabis in medicine. Here are three biotech stocks moving headfirst into cannabis medicine.
Zynerba landed a new patent for its Zygel product to use cannabidiol as a treatment for Autism Spectrum Disorder, sending ZYNE stock ripping.
The CBD trend is heating up as its multiple uses gain traction and laws enable its use. Here are seven marijuana stocks to buy.
Investors have heard a ton about cannabis stocks and their ridiculous valuations. But Wall Street analysts say these pot stocks still have a lot of upside ahead.
Zynerba has a CBD gel that looks like a promising treatment for various neurological diseases. What does it mean for ZYNE stock?
There's some positive Zynerba Pharmaceuticals news concerning ZYNE stock on Tuesday that has it soaring to incredible heights.
Things may be looking up for marijuana stocks, as a cannabidiol (CBD)-based drug was rescheduled to Schedule 5. These 2 should profit next.
Zynerba's stock sank after the company issued shares at $8. This validated the bearish bets against the stock. What should investors expect next?
InvestorPlace's Best Stocks Contest is entering the homestretch! Here's how our experts' picks are holding up through the third quarter.
3 Stocks to Watch on Monday: Alphabet Inc (GOOGL), Zynerba Pharmaceuticals Inc (ZYNE) and Sony Corp (ADR) (SNE)
Zynerba Pharmaceuticals (ZYNE) crashes by nearly half, Alphabet (GOOGL) responds to anti-diversity letter and Sony (SNE) suffers yet another box-office disappointment.
Former leaders have fallen and former laggards in the Best Stocks for 2017 contest have risen to the occasion -- check out the rankings!
The experts' pick in the 10 Best Stocks for 2017 contest are trouncing the market so far. But where will these stocks to buy go from here?
Zynerba is working to bring its marijuana-based medications through trials and investors seem to be rewarding ZYNE stock.
For marijuana stocks like GWPH, ZYNE and INSY, a federal crackdown on marijuana legalization laws is no big deal.
The following stocks were the biggest movers and shakers in the Manufacturing sector today.
The Manufacturing sector saw plenty of trading activity today, including the following leaders and losers.
ZYNE stock has a couple of promising therapies in trials that could make 2017 a great year for Zynerba stockholders.
From Market News Video
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100..
Navellier RatingsPowered by Portfolio Grader
10 Stocks Set for Monster Growth
He found Apple at $4… Oracle at $6… Amazon at $40… Now legendary growth investor Louis Navellier is giving away his latest Research Report — for FREE!
Download your FREE COPY!